The arylamine N-acetyltransferase (NAT2) polymorphism and the risk of adverse reactions to co-trimoxazole in children

Molecular mechanism of slow acetylation of drugs and carcinogens in humans.

Martin Blum, A Demierre, Denis M. Grant et al. · Proceedings of the National Academy of Sciences · 1991 · 347 citations

Life Sciences, Genetics, Molecular Genetics +14

Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.

Ingolf Cascorbi, Nikolaos Drakoulis, Jürgen Brockmöller et al. · PubMed · 1995 · 335 citations

Life Sciences, Genetics, Molecular Genetics +8

SHORT COMMUNICATION: Genotype/phenotype discordance for human arylamine <i>N</i>-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans

Douglas A. Bell, Jack A. Taylor, Marguerite A. Butler et al. · Carcinogenesis · 1993 · 292 citations

Life Sciences, Genetics, Molecular Genetics +11

Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions

Michael Rieder, Neil H. Shear, Allan Kanee et al. · Clinical Pharmacology & Therapeutics · 1991 · 218 citations

Medicine, Pharmacology, Hypersensitivity +9

Sulfamethoxazole is metabolized to the hydroxylamine in humans

Alastair E. Cribb, Stephen P. Spielberg · Clinical Pharmacology & Therapeutics · 1992 · 175 citations

Medicine, Pharmacokinetics, Pharmacology +17